These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Ter Hark SE; Jamain S; Schijven D; Lin BD; Bakker MK; Boland-Auge A; Deleuze JF; Troudet R; Malhotra AK; Gülöksüz S; Vinkers CH; Ebdrup BH; Kahn RS; Leboyer M; Luykx JJ J Psychopharmacol; 2020 May; 34(5):524-531. PubMed ID: 32126890 [TBL] [Abstract][Full Text] [Related]
3. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. Maciukiewicz M; Tiwari AK; Zai CC; Gorbovskaya I; Laughlin CP; Nurmi EL; Liebermann JA; Meltzer HY; Kennedy JL; Müller DJ Schizophr Res; 2019 Oct; 212():204-212. PubMed ID: 31447353 [TBL] [Abstract][Full Text] [Related]
5. Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. Yoshida K; Maciukiewicz M; Zai CC; Gonçalves VF; Brandl EJ; Lieberman JA; Meltzer HY; Tiwari AK; Kennedy JL; Müller DJ Prog Neuropsychopharmacol Biol Psychiatry; 2020 Aug; 102():109952. PubMed ID: 32335267 [TBL] [Abstract][Full Text] [Related]
6. Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial. Nasib LG; Winter-van Rossum I; Zuithoff NPA; Boudewijns ZSRM; Leucht S; Kahn RS J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36988483 [No Abstract] [Full Text] [Related]
7. Predicting antipsychotic-induced weight gain in first episode psychosis - A field-wide systematic review and meta-analysis of non-genetic prognostic factors. Fitzgerald I; Sahm LJ; Byrne A; O'Connell J; Ensor J; Ní Dhubhlaing C; O'Dwyer S; Crowley EK Eur Psychiatry; 2023 Jun; 66(1):e42. PubMed ID: 37278237 [TBL] [Abstract][Full Text] [Related]
8. Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. Maciukiewicz M; Gorbovskaya I; Tiwari AK; Zai CC; Freeman N; Meltzer HY; Kennedy JL; Müller DJ J Neural Transm (Vienna); 2019 Jan; 126(1):27-33. PubMed ID: 30229349 [TBL] [Abstract][Full Text] [Related]
9. Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain. Schreyer KF; Leucht S; Heres S; Steimer W Psychopharmacology (Berl); 2023 Apr; 240(4):899-908. PubMed ID: 36757449 [TBL] [Abstract][Full Text] [Related]
10. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Gonçalves VF; Zai CC; Tiwari AK; Brandl EJ; Derkach A; Meltzer HY; Lieberman JA; Müller DJ; Sun L; Kennedy JL Neuropsychopharmacology; 2014 May; 39(6):1347-54. PubMed ID: 24196945 [TBL] [Abstract][Full Text] [Related]
11. [Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis]. Luykx JJ; Kraats GV; van Ojen R Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31647624 [TBL] [Abstract][Full Text] [Related]
12. Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. Tiwari AK; Zhang D; Pouget JG; Zai CC; Chowdhury NI; Brandl EJ; Qin L; Freeman N; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ World J Biol Psychiatry; 2018; 19(sup3):S97-S105. PubMed ID: 27855565 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu AV; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Gray R; Lancet Psychiatry; 2018 Jul; 5(7):553-563. PubMed ID: 29880238 [TBL] [Abstract][Full Text] [Related]
14. Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort. Levi L; Bar Haim M; Burshtein S; Winter-Van Rossum I; Heres S; Davidson M; Shenkman G; Kahn RS; Weiser M Eur Neuropsychopharmacol; 2020 Mar; 32():131-135. PubMed ID: 32037127 [TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications. Yu H; Wang L; Lv L; Ma C; Du B; Lu T; Jin C; Yan H; Yang Y; Li W; Ruan Y; Zhang H; Zhang H; Mi W; Mowry B; Ma W; Li K; Zhang D; Yue W Schizophr Bull; 2016 May; 42(3):814-23. PubMed ID: 26656879 [TBL] [Abstract][Full Text] [Related]
16. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Vanelle JM; Douki S Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759 [TBL] [Abstract][Full Text] [Related]
17. Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Srisawat U; Reynolds GP; Zhang ZJ; Zhang XR; Arranz B; San L; Dalton CF Int J Neuropsychopharmacol; 2014 Mar; 17(3):485-90. PubMed ID: 24229535 [TBL] [Abstract][Full Text] [Related]
18. Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Glatard A; Guidi M; Delacrétaz A; Dubath C; Grosu C; Laaboub N; von Gunten A; Conus P; Csajka C; Eap CB Clin Pharmacokinet; 2020 Mar; 59(3):371-382. PubMed ID: 31552612 [TBL] [Abstract][Full Text] [Related]
20. Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation. Liao Y; Yu H; Zhang Y; Lu Z; Sun Y; Guo L; Guo J; Kang Z; Feng X; Sun Y; Wang G; Su Z; Lu T; Yang Y; Li W; Lv L; Yan H; Zhang D; Yue W Mol Psychiatry; 2024 Jun; 29(6):1857-1868. PubMed ID: 38336841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]